Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 2/20 | 0.60 |
| ▸ | METAP1 | P53582 | 2/20 | 0.60 |
| ▸ | CBFB | Q13951 | 1/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.58 |
| ▸ | RAB9A | P51151 | 4/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5952973 | 0.84 | METAP2 (0.57) | METAP2METAP1CBFBNPC1ALDH1A1 | |
| SCHEMBL1528347 | 0.82 | NPC1 (0.58) | METAP2METAP1NPC1RAB9APKM | |
| SCHEMBL18415732 | 0.82 | NPC1 (0.59) | METAP2METAP1CBFBNPC1RAB9A | |
| SCHEMBL5953199 | 0.81 | AURKA (0.58) | METAP2METAP1CBFBNPC1RAB9A | |
| SCHEMBL13850422 | 0.80 | AURKA (0.48) | METAP2METAP1CBFBNPC1RAB9A | |
| SCHEMBL35044 | 0.79 | AURKA (0.56) | METAP2METAP1CBFBNPC1RAB9A | |
| SCHEMBL34815 | 0.78 | NPC1 (0.58) | METAP2METAP1CBFBNPC1RAB9A | |
| SCHEMBL20677813 | 0.78 | NPC1 (0.75) | METAP2METAP1CBFBNPC1RAB9A | |
| SCHEMBL13599850 | 0.78 | NPC1 (0.81) | METAP2METAP1CBFBNPC1RAB9A | |
| SCHEMBL5953465 | 0.77 | AURKA (0.54) | METAP2METAP1CBFBNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | claimed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | claimed |
| US-8288425-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2012-10-16 | — | — | US | disclosed |
| US-20060014756-A1 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2006-01-19 | — | — | US | disclosed |
| US-6897208-B2 | Benzimidazoles | AVENTIS PHARMACEUTICALS INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1441725-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | Aventis Pharmaceuticals Inc. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20040048868-A1 | Benzimidazoles | AVENTISUB LLC | 2004-03-11 | — | — | US | disclosed |
| WO-2003035065-A1 | BENZIMIDAZOLES AND ANALOGUES AND THEIR USE AS PROTEIN KINASES INHIBITORS | AVENTIS PHARMACEUTICALS INC (US) | 2003-05-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014756-A1 | Benzimidazoles | CDK9, BMX, SBK3 | METAP2 3625/4885METAP1 3011/4885CBFB 3643/4885 |
| US-20040048868-A1 | Benzimidazoles | CDK9, BMX, CDKN1A | METAP2 3741/4885METAP1 1932/4885CBFB 4136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.